🚨 New Publication🚨 Very excited to share this collaboration with Joe Levy & Jerry Anderson on the comparison of #drugprice index methods to assess price #inflation. 🧵 (1/11) jamanetwork.com/journals/jama-…

Price inflation methods fail to account for new drugs, mix of brand and generic & differences in Rx duration. Study illustrates how methods influence inflation estimates & offers a class-based approach that incorporates Rx duration. ja.ma/3ClXAEA Joey Mattingly Joe Levy

New working paper with Joe Levy examines how Part D plans cover drugs based on how they are priced relative to an estimate of their clinical value. aei.org/research-produ…

Hey #ARM23 attendees, looking for one last session to close out an amazing few days? Check out this late-breaking session: “Medicare and Drug Pricing and Spending” today at 10:30am. Come learn about findings from the Transparency in Coverage insurance disclosed pricing data!

Great morning discussing health care price transparency and patients out of pocket costs at #IHEA2023 Kelly Anderson Angela Liu Mark Meiselbach @michalhorny Kevin Griffith Ashley Leech

My new NEJM Perspective with Sean Tunis: CMSGov is becoming a major #HTA organization. It should embrace the role. tinyurl.com/3f56499a CEVR Tufts Medical Center Arnold Ventures HTAi UW School of Pharmacy @SchaefferCenter Stacie Dusetzina #heor Anna Kaltenboeck Joey Mattingly

New paper out in Health Affairs In Medicare Advantage, less use of longitudinal home-based medical care but substantially greater use of one-time home-based medical visits (likely related to diagnosis coding) than in traditional Medicare healthaffairs.org/doi/full/10.13…

CMS will use comparative effectiveness to adjust the starting point in price negotiations, but how exactly? We adapted the French system (added benefit ratings linked to domestic reference prices) to model one approach and estimate savings. Joe Levy valueinhealthjournal.com/article/S1098-…

Defining “the price” of brand drugs like Ozempic can be complex. Our white paper summarizes what we know about the prices of new treatments for diabetes and obesity Short story: Very big differences between list and net prices, even adjusting for coupons aei.org/research-produ…

Now in print, Joe Levy and I test whether coverage of brand drugs in Part D differs based on whether the drug is a "good" or "bad" value relative to cost-effectiveness estimates. In short, it does not. aei.org/research-produ…

Hmm: New American Enterprise Institute study estimates huge #GrossToNetBubble for GLP-1 #drugs. Net prices far below list prices due to #PBM #rebates & manuf copay support 👇 Perhaps economic impact has been overestimated? Full report: drugch.nl/3tiWRCB

Ozempic, Wegovy, and other GLP-1s perfectly illustrate the common (and large) gaps between list and net prices of many brand drugs. A summary of our work: "Ozempic and Wegovy Don’t Cost What You Think They Do" via The New York Times nytimes.com/2023/10/22/hea…

FDA approval of 2nd potent GLP-1 for treatment of obesity - Lilly’s drug Zepbound - will accelerate discounting as competition heats up, reducing costs and extending access to patients. A prior AEI Economics analysis captured magnitude of earlier discounts aei.org/wp-content/upl…

We've drafted a response to the recent CMS RFI on additional data collection to study the Medicare Advantage program. Want to sign on? Send me an email by Friday March 8th docs.google.com/document/d/1T1…

🚨 New publication alert 🚨 I am so excited to share that I published part of my dissertation work in JAMA HF. A huge thank you to these co-authors: Kelly Anderson, Joe Levy, Daniel Polsky, and the twitterless Thomas V Johnson and Jerry Anderson jamanetwork.com/journals/jama-…

And go.....

Tough day for a 🚨new paper🚨, but nevertheless! How much would it cost if Medicare was allowed to cover drugs approved for weight loss? We estimate $3.1-6.1 billion per year in the near term. Just out in Health Affairs (with Joe Levy) healthaffairs.org/doi/10.1377/hl…

Very interesting to get a deeper look at what Medicare coverage of the weight loss drugs might cost, taking into account existing rebates & considering the counterfactual that many are likely to gain coverage through other indications over time regardless.

AHRQ-funded researchers calculated the US could save $150M every year by switching from low molecular weight heparin to aspirin for blood clot prevention in orthopedic trauma patients. (That grant cost <$100K.) pubmed.ncbi.nlm.nih.gov/40668732/